Liver cancer is a highly malignant tumor and is one of the malignant tumors that seriously threaten human life and health. The incidence rate of liver cancer in China ranks the first in the world, and the mortality rate of liver cancer in China is also the highest in the world. At present, the preferred treatment for liver cancer is surgical resection or intervention plus surgery. However, most of the patients have already reached the middle and late stages of liver cancer when they come to the hospital, losing the best time for surgery. For patients who cannot be operated, interventional treatment not only greatly improves the survival quality and survival period of patients with middle and late stage hepatocellular carcinoma, but also is comparable to the treatment of patients with early stage hepatocellular carcinoma resected by surgery. At present, the main interventional treatments for hepatocellular carcinoma in China are: transhepatic artery chemoembolization (TACE), high-intensity ultrasound focused knife, radiofrequency ablation, percutaneous anhydrous alcohol injection, gamma knife, argon helium knife cryosurgery, three-dimensional conformal radiotherapy and gene introduction therapy. Transhepatic artery chemoembolization is based on the fact that 95-99% of blood supply of hepatocellular carcinoma comes from hepatic artery, only a small part comes from portal vein blood supply, while only 25-30% of blood supply of normal liver tissue comes from hepatic artery. At present, TACE is the main method of hepatocellular carcinoma intervention. Firstly, selective catheter insertion into the hepatic artery for infusion of chemotherapeutic drugs can make the local tissue drug concentration in the liver 100-400 times higher than the systemic concentration, while the drug concentration in the tumor area is 5-20 times higher than that in normal liver tissue. TACE has been widely used in the treatment of hepatocellular carcinoma, such as the treatment of middle and late stage hepatocellular carcinoma which has lost the chance of surgery, early stage small hepatocellular carcinoma, preventive treatment before surgical resection of hepatocellular carcinoma, and preventive treatment after surgical resection of hepatocellular carcinoma. Ma Cunkai, Department of Interventional Medicine, Affiliated Hospital of Qinghai University